German hope for endometrial and ovarian cancer sufferers
This article was originally published in Clinica
Too many German women die unnecessarily because ovarian and womb cancer are diagnosed too late to offer them any chance of effective treatment, claims German Cancer Aid. In an effort to address the situation, the society is sponsoring an initiative by Peter Altevogt from the Cancer Research Centre in Heidelberg (KFZH) and Mina Fogel from the Kaplan Hospital in Rehovot, Israel, to the tune of E194,000 ($196,000). The institutions have developed a new diagnostic method for cancer detection by identifying a protein that they believe could serve as a tumour marker.
You may also be interested in...
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.
In a final guidance from the US agency, regulators say most combination product questions are best resolved through traditional pathways and noted that initiating a so-called combination product agreement meeting may be unproductive.